Healthcare
Guardant Health, Inc.(GH)
Live Price
Offline$131.78
+2.07% today
1Y Change
+160.16%
Window
Jun 25, 2025 โ Jun 15, 2026
- Market Cap
- $11.16B
- Revenue Growth
- +32.9%
- EPS Growth
- +6.7%
- Dividend Yield
- 0.0%
Coverage: 244 bars ยท Jun 25, 2025 โ Jun 15, 2026
Research Briefing
A compact read on the setup, peer context, quarterly changes, and recent earnings reaction.
Research Snapshot
Guardant Health, Inc. (GH) is a Healthcare stock with a market cap of $11.16B and listed on NASDAQ. The stock last traded around $131.78 and up 160.2% across the available one-year price window (Jun 25, 2025 โ Jun 15, 2026). Baseline metrics include revenue growth of +32.9%, EPS growth of +6.7%, a dividend yield of 0.0%. What stands out right now is revenue +32.9%, EPS +6.7%, free cash flow +15.2% with operating margin -44.5% and ROIC -25.5%. Valuation already assumes a fairly strong business story at price/sales 11.4. Overall, the current profile looks closer to a higher-growth but lower-margin setup than a generic broad-market placeholder. Stock Foundry combines GH price history, valuation, growth, dividend context, earnings, analyst forecasts, news, related Healthcare peers on this page.
Sector Context
How this name stacks up against nearby peers on first-pass metrics.
Revenue Growth
Above sector median
+32.9% vs +7.6% peer median
Operating Margin
Below sector median
-44.5% vs +19.4% peer median
What Changed This Quarter
Latest report context and the signals most likely to have changed the story.
Latest report is on the board
2026 was reported on Apr 29, 2026, but the surprise data is still limited.
The operating story is still moving forward
Revenue is running at +32.9% and EPS at +6.7%, with operating margin around -44.5%.
Earnings Reaction Memory
How the stock has tended to move after recent reports.
Across the last 3 reported quarters, the stock averaged +11.4% over the next 5 trading days and finished higher after 2 of those reports.
View quarter-by-quarter reaction table
| Quarter | EPS ฮ | 1D | 5D | 20D |
|---|---|---|---|---|
2026 Apr 29, 2026 | โ | +4.4% | +10.6% | +59.7% |
2026 Feb 19, 2026 | -17.4% | -3.1% | -7.9% | -16.3% |
2025 Oct 29, 2025 | +18.8% | +27.9% | +31.5% | +49.1% |
Benchmark Edge
GH vs SPY, QQQ, and Sector ETFs
Normalized return, excess return, max drawdown, and calendar-year wins against the benchmarks investors actually use.
GH
โ
Normalized return
SPY
--
S&P 500
Excess Return
--
Relative to SPY
GH Max Drawdown
-32.98%
Trailing 1Y
SPY Max Drawdown
โ
Trailing 1Y
Calendar-Year Returns
Uses the longest available daily history for GH and SPY.
Company Overview
Guardant Health, Inc.
NASDAQ Global Select
Guardant Health, Inc., a precision oncology company, provides blood tests, data sets, and analytics in the United States and internationally. The company offers Guardant360, Guardant360 LDT, Guardant360 CDx, and GuardantOMNI liquid biopsy-based tests for advanced stage cancer; and GuardantINFORM, an in-silico research platform that comprise a clinical-genomic liquid biopsy dataset of advanced cancer patients. It is also developing LUNAR-2 test for the early detection of colorectal cancer in asymptomatic individuals eligible; and GuardantConnect, an integrated software-based solution for clinical and biopharmaceutical customers seeking to connect patients tested with the Guardant360 assay with actionable alterations with potentially relevant clinical trials. In addition, the company offers Guardant Reveal Test for neoadjuvant and adjuvant treatment selection in early-stage cancer patients; Guardant360 tissue genotyping product; and Guardant-19 for use in the detection of the novel coronavirus. Further, it offers development services, including companion diagnostic development and regulatory approval, clinical study setup, monitoring and maintenance, testing development and support, and kits fulfillment related services to biopharmaceutical companies and medical institutions. The company was incorporated in 2011 and is headquartered in Redwood City, California.
- Leadership
- Helmy Eltoukhy
- IPO Date
- Oct 4, 2018
- Employees
- 2.0k
- Street Address
- 505 Penobscot Drive
- Mailing
- Palo Alto, CA, 94063
- Region
- Palo Alto, CA, US
- Reporting Currency
- USD
- Investor Line
- 855 698 8887
- Last Updated
- Apr 29, 2026
Key Fundamentals
Valuation, growth, profitability, and balance sheet signals.
Valuation
- P/E
- โ
- EV/EBITDA
- โ
- Price/Sales
- 11.4
- Price/Book
- โ
Growth
- Revenue
- +32.9%
- EPS
- +6.7%
- Free Cash Flow
- +15.2%
Profitability
- Gross Margin
- 64.5%
- Operating Margin
- -44.5%
- Net Margin
- -42.4%
- ROE
- 164.9%
- ROIC
- -25.5%
Balance Sheet
- Debt/Equity
- โ
- Current Ratio
- 4.84
Earnings Reports
Latest News
Official Releases
Company announcements and filings-style updates.
Next Step
Keep the research moving
After the overview, the strongest next step is usually chart context or a tighter compare set.